Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants

Antimicrob Agents Chemother. 2007 Jun;51(6):2208-10. doi: 10.1128/AAC.00871-06. Epub 2007 Apr 9.

Abstract

Saquinavir boosted with low-dose ritonavir given with zidovudine and lamivudine was well tolerated by pregnant women and their infants. All mothers had <400 human immunodeficiency virus type 1 RNA copies/ml at delivery. Two had elevated liver transaminases and amylase. Seven infant adverse events were possibly treatment related (anemia, neutropenia, and hyperbilirubinemia).

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-HIV Agents* / administration & dosage
  • Anti-HIV Agents* / adverse effects
  • Anti-HIV Agents* / therapeutic use
  • Drug Therapy, Combination
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1 / drug effects
  • Humans
  • Infant
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical / prevention & control
  • Microbial Sensitivity Tests
  • Mothers
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Pregnancy Complications, Infectious / virology
  • RNA, Viral / blood
  • Reverse Transcriptase Inhibitors* / administration & dosage
  • Reverse Transcriptase Inhibitors* / adverse effects
  • Reverse Transcriptase Inhibitors* / therapeutic use
  • Ritonavir* / administration & dosage
  • Ritonavir* / adverse effects
  • Ritonavir* / therapeutic use
  • Saquinavir* / administration & dosage
  • Saquinavir* / adverse effects
  • Saquinavir* / therapeutic use
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Saquinavir
  • Ritonavir